ESH E-Conference: 2nd How to Diagnose and Treat
CML / MPN
February 25-28, 2021
DISCLOSURES
E. ABRUZZESE N/A
H. K. AL-ALI Celgene - BMS Research Support, Consultant, Scientific Advisory Bd.
Incyte Research Support
Novartis Research Support, Consultant, Scientific Advisory Bd.
A. ALVAREZ LARRAN AOP Scientific Advisory Bd.
BMS / Celgene Scientific Advisory Bd.
Novartis Research Support
J. APPERLEY Bristol Myers Squibb Speakers' Bureau, Scientific Advisory Bd.
Incyte Research Support, Speakers' Bureau, Scientific Advisory Bd.
Novartis Research Support, Speakers' Bureau, Scientific Advisory Bd.
Pfizer Research Support, Speakers' Bureau, Scientific Advisory Bd.
T. BARBUI No affiliation
A. BURCHERT AOP Research Support, Scientific Advisory Bd.
BMS Research Support
Novartis Research Support
Pfizer Scientific Advisory Bd.
E. CHELYSHEVA BMS Speakers' Bureau
Novartis Speakers' Bureau
Pfizer Speakers' Bureau
N. CROSS Incyte Scientific Advisory Bd.
Novartis Research Support, Scientific Advisory Bd.
T. ERNST No affiliation
N. GANGAT Actuate Therapeutics Research Support
Gilead Research Support
Janssen Research Support
Sierra Oncology Research Support
Takeda Research Support
H. GISSLINGER AOP Orphan Pharma Research Support, Consultant, Speakers' Bureau, Scientific Advisory Bd.
Celgene Consultant, Scientific Advisory Bd.
Jansen Cilag Speakers' Bureau
Novartis Research Support, Consultant, Speakers' Bureau, Scientific Advisory Bd.
J. GOTLIB Incyte Research Support, Scientific Advisory Bd.
Novartis Research Support, Scientific Advisory Bd.
Kartos Research Support, Scientific Advisory Bd.
Blueprint Medicines Research Support, Scientific Advisory Bd.
Deciphera Research Support, Scientific Advisory Bd.
Abbvie Research Support, Scientific Advisory Bd.
Celgene Research Support
BMS Research Support
Protagonist therapeutics Research Support, Scientific Advisory Bd.
CTI Scientific Advisory Bd.
Biopharma Research Support
Promedior Research Support
PharmaEssentia Scientific Advisory Bd.
M. GRIESSHAMMER AOP Orphan Speakers' Bureau, Scientific Advisory Bd.
P. GUGLIELMELLI Abbvie Scientific Advisory Bd.
Novartis Scientific Advisory Bd.
SCIENTIFIC PROGRAMME
SESSION I
OPTIMIZING
CYTOREDUCTION
SESSION II
MANAGEMENT OF CML
WITH TKI
SESSION III
MPN RISK
STRATIFICATION
INCLUDING VASCULAR
EVENTS
DEBATE 1
INTERFERON ALPHA
SHOULD BE FRONT LINE
THERAPY IN ALL ET/PV
PATIENTS
ROUNDTABLE 1
INFECTIONS IN
MYELOPROLIFERATIVE
DISORDERS, INCLUDING
CML
ROUNDTABLE 2
PREGNANCY AND
PARENTING
DEBATE 2
ALLOGENEIC STEM CELL
TRANSPLANTATION
SHOULD BE CONSIDERED
THIRD LINE OPTION IN
CHRONIC PHASE CML
SESSION IV
EVOLVING THERAPIES
IN MYELOFIBROSIS
SESSION V
MANAGEMENT OF
ADVANCED AND UNUSUAL
DISEASE (MPN AND CML)
SESSION VI
TREATMENT FREE
REMISSION IN CML
KEYNOTE LECTURE
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FO R A POSTER
PRESENTATION
DISCLOSURES